---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-008839"
form_type: "8-K"
ticker: "RNAZ"
cik: "0001829635"
company_name: "Transcode Therapeutics, Inc."
filed_at: "2024-01-31T23:59:59+00:00"
generated_at: "2026-06-06T14:02:33.710291+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# TransCode regains Nasdaq equity compliance; still faces bid price rule non-compliance with May 6 deadline

## Summary
- Nasdaq determined TransCode met minimum $2.5M stockholders' equity requirement for continued listing.
- Company placed on mandatory panel monitor through January 26, 2025, subject to delisting if non-compliant again.
- Separately, TransCode remains non-compliant with minimum $1.00 bid price rule; must cure by May 6, 2024.
- Failure to meet bid price rule could lead to additional 180-day compliance period if other listing standards are met.

## SEC filing metadata
- accession: 0001104659-24-008839
- form_type: 8-K
- ticker: RNAZ
- cik: 0001829635
- company_name: Transcode Therapeutics, Inc.
- filed_at: 2024-01-31T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829635/000110465924008839/0001104659-24-008839-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829635/000110465924008839/tm244740d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-008839
- JSON: https://secwatch.observer/filing/0001104659-24-008839.json
- Plain text: https://secwatch.observer/filing/0001104659-24-008839.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.